A previous example is the protease γ-secretase where development of inhibitors was discontinued as AD treatment because they did not only block APP cleavage, but also cleavage and function of other γ-secretase substrates, in particular Notch [109, 110]. This evidence concerns the gene APP and Alzheimer disease.